Women's Health Through Neuroendocrine Influences on Mood and Cognitive Function

Abstract

Neuroendocrine mechanisms play a central role in shaping women's mood and cognitive function across the lifespan. Fluctuations in ovarian hormones, particularly estrogen and progesterone, modulate neurotransmitter systems, neuroplasticity, and neural circuitry, thereby influencing affective and cognitive domains. This review synthesizes current epidemiological, mechanistic, and clinical insights into neuroendocrine influences on mood and cognition in women, emphasizing the impact of reproductive transitions, risk factors, diagnostic approaches, and evidence-based management strategies. Recent advances in neuroendocrinology and guideline recommendations are discussed, with a focus on optimizing women's mental and cognitive health in clinical practice.

Introduction

Women's mental and cognitive health is profoundly influenced by neuroendocrine factors, which mediate the interplay between the central nervous system and hormonal fluctuations throughout life. Periods such as puberty, menstrual cycles, pregnancy, postpartum, and the menopausal transition present unique neuroendocrine challenges, often manifesting as mood disturbances or cognitive changes. Understanding these mechanisms provides clinicians with deeper insight into the pathogenesis and management of affective and cognitive disorders in women, facilitating more precise and personalized care.

Epidemiology / Disease Burden

Women have a higher prevalence of mood disorders, including depression and anxiety, compared to men, with lifetime risk estimates for major depressive disorder reaching up to 21% in women versus 13% in men. Cognitive complaints, such as memory lapses and executive dysfunction, are also more frequently reported by women, particularly during perimenopause and menopause, affecting quality of life and functional status. These disorders contribute significantly to global disease burden, disability, and healthcare utilization, underscoring the importance of neuroendocrine considerations in women's health.

Pathophysiology

The neuroendocrine system integrates hormonal signals with brain function, modulating mood and cognition through complex pathways. Estrogen and progesterone influence synaptic plasticity, neurogenesis, and the regulation of key neurotransmitters, including serotonin, dopamine, and gamma-aminobutyric acid (GABA). Estrogen enhances serotonergic transmission and exerts neuroprotective effects, while progesterone-derived neurosteroids modulate GABAergic tone, influencing anxiety and mood stability. Disruptions in hypothalamic-pituitary-gonadal (HPG) axis activity during reproductive transitions can destabilize these mechanisms, predisposing women to mood and cognitive changes. Additionally, interactions with the hypothalamic-pituitary-adrenal (HPA) axis and inflammatory mediators further modulate neural outcomes.

Risk Factors

Several risk factors modulate the neuroendocrine impact on women's mood and cognitive function. Genetic predisposition, previous psychiatric history, adverse childhood experiences, and chronic stress interact with hormonal fluctuations to increase vulnerability. Reproductive life events such as menarche, pregnancy, postpartum period, and menopause are critical windows of heightened risk. Medical comorbidities (e.g., thyroid dysfunction, polycystic ovary syndrome) and lifestyle factors (e.g., poor sleep, sedentary behavior) also contribute to neuroendocrine dysregulation and adverse clinical outcomes.

Clinical Features

Neuroendocrine-related mood disturbances in women commonly present as depressive symptoms, irritability, anxiety, and emotional lability. Cognitive complaints may include subjective memory impairment, decreased attention, and diminished executive function. Symptom severity often correlates with hormonal transitions, as seen in premenstrual dysphoric disorder (PMDD), perinatal depression, and menopausal cognitive decline. Notably, these symptoms can overlap with primary psychiatric or neurological disorders, necessitating careful clinical evaluation.

Diagnosis

Accurate diagnosis relies on thorough history-taking, with attention to temporal patterns of mood and cognitive symptoms relative to hormonal milestones. Standardized rating scales, such as the Edinburgh Postnatal Depression Scale or the Menopause Rating Scale, can aid in quantifying symptom burden. Laboratory evaluation may include assessment of thyroid function, reproductive hormones (FSH, LH, estradiol, progesterone), and exclusion of metabolic or neurologic etiologies. Neuroimaging is reserved for atypical presentations or suspected structural pathology.

Treatment & Management

Management approaches are multifaceted, tailored to the underlying neuroendocrine mechanism and clinical context. Hormonal therapies, such as combined oral contraceptives or menopausal hormone therapy (MHT), are considered in select cases, particularly for moderate to severe symptoms linked to hormonal transitions. Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), are effective for mood stabilization, including in PMDD and perimenopausal depression. Non-pharmacological interventions cognitive-behavioral therapy, lifestyle modifications (exercise, sleep hygiene), and stress reduction play a critical adjunctive role. Multidisciplinary care, including collaboration with endocrinology and psychiatry, is often required for optimal outcomes.

Recent Advances / Emerging Therapies

Recent research has illuminated the role of neurosteroids, such as allopregnanolone, in mood regulation, leading to novel treatments like brexanolone for postpartum depression. Advances in neuroimaging and molecular biomarkers are enhancing diagnostic precision and risk stratification. Individualized hormone therapy regimens, incorporating transdermal delivery and bioidentical preparations, are under investigation for cognitive and mood benefits with minimized systemic risks. The burgeoning field of neuroimmunology also highlights the influence of inflammatory mediators in modulating neuroendocrine-brain interactions.

Guideline Recommendations

Major guidelines, including those from the American Psychiatric Association and the North American Menopause Society, emphasize a personalized, evidence-based approach to neuroendocrine-related mood and cognitive disorders in women. They recommend integrating symptom monitoring with hormonal assessments, employing both pharmacological and non-pharmacological interventions, and considering the risk–benefit profile of hormone therapies. Shared decision-making, patient education, and ongoing monitoring are highlighted as best practices.

Conclusion

Neuroendocrine factors are pivotal in the etiology and clinical expression of mood and cognitive disturbances in women. Integrating mechanistic understanding with evidence-based diagnostic and therapeutic strategies enhances the ability of clinicians to address these issues across the reproductive lifespan. Ongoing research and guideline development are expected to further refine individualized approaches, improving outcomes and quality of life for women affected by neuroendocrine-mediated mood and cognitive disorders.